Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Serum Test for Ovarian Cancer Helps Determine Type of Required Surgery

By LabMedica International staff writers
Posted on 17 Sep 2009
Ovarian cancer can be detected in a pelvic mass that is already known to require surgery, helping patients and health care professionals decide what type of surgery should be done and by whom.

Called OVA1, the qualitative serum test for ovarian cancer combines the results of five immunoassays into a single numerical score. More...
The test is indicated for women who meet the following criteria: the patient is over age 18, an ovarian adnexal mass is present for which surgery is planned, and the patient has not yet been referred to an oncologist.

The immunoassay identifies five well-established biomarkers --- Transthyretin (TT or prealbumin), Apolipoprotein A-1 (Apo A-1), Beta2-Microglobulin (Beta2M), Transferrin (Tfr) and Cancer Antigen 125 (CA 125 II). An algorithm is then used to determine the likelihood of malignancy in women with pelvic mass for whom surgery is planned.

OVA1test was developed by Vermillion, Inc. (Freemont, CA, USA) a molecular diagnostics company, in cooperation with Quest Diagnostics (Madison, NJ, USA), a provider of cancer diagnostics. Quest Diagnostics has exclusive rights to offer the test to the clinical reference laboratory market in the U.S. for three years. The U.S. Food and Drug Administration (FDA) has cleared the OVA1 test, as an indication of ovarian cancer with high sensitivity prior to biopsy or exploratory surgery, even when radiological test results fail to indicate malignancy.

The test should not be used without an independent clinical/radiological evaluation. It is not intended to be a screening test or to determine whether a patient should proceed to surgery. Incorrect use of the OVA1 test carries the risk of unnecessary testing, surgery, and/or delayed diagnosis.

Vermillion, Inc. is dedicated to the discovery, development, and commercialization of novel high-value diagnostic tests that help physicians diagnose, treat, and improve outcomes for patients. Vermillion has diagnostic programs in oncology, hematology, cardiology, and women's health.

Quest Diagnostics is a provider of diagnostic testing, information, and services that patients and doctors need to make better healthcare decisions. The company offers access to diagnostic testing services through its network of laboratories and patient service centers, and provides interpretive consultation through its medical and scientific staff.

Related Links:
Vermillion, Inc.
Quest Diagnostics


Gold Member
Collection and Transport System
PurSafe Plus®
POC Helicobacter Pylori Test Kit
Hepy Urease Test
Sperm Quality Analyis Kit
QwikCheck Beads Precision and Linearity Kit
Anterior Nasal Specimen Collection Swabs
53-1195-TFS, 53-0100-TFS, 53-0101-TFS, 53-4582-TFS
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: The diagnostic device can tell how deadly brain tumors respond to treatment from a simple blood test (Photo courtesy of UQ)

Diagnostic Device Predicts Treatment Response for Brain Tumors Via Blood Test

Glioblastoma is one of the deadliest forms of brain cancer, largely because doctors have no reliable way to determine whether treatments are working in real time. Assessing therapeutic response currently... Read more

Microbiology

view channel
Image: New evidence suggests that imbalances in the gut microbiome may contribute to the onset and progression of MCI and Alzheimer’s disease (Photo courtesy of Adobe Stock)

Comprehensive Review Identifies Gut Microbiome Signatures Associated With Alzheimer’s Disease

Alzheimer’s disease affects approximately 6.7 million people in the United States and nearly 50 million worldwide, yet early cognitive decline remains difficult to characterize. Increasing evidence suggests... Read more

Technology

view channel
Image: Vitestro has shared a detailed visual explanation of its Autonomous Robotic Phlebotomy Device (photo courtesy of Vitestro)

Robotic Technology Unveiled for Automated Diagnostic Blood Draws

Routine diagnostic blood collection is a high‑volume task that can strain staffing and introduce human‑dependent variability, with downstream implications for sample quality and patient experience.... Read more

Industry

view channel
Image: Roche’s cobas® Mass Spec solution enables fully automated mass spectrometry in routine clinical laboratories (Photo courtesy of Roche)

New Collaboration Brings Automated Mass Spectrometry to Routine Laboratory Testing

Mass spectrometry is a powerful analytical technique that identifies and quantifies molecules based on their mass and electrical charge. Its high selectivity, sensitivity, and accuracy make it indispensable... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.